Chartwell Investment Partners LLC grew its holdings in Laboratory Corp. of America Holdings (NYSE:LH) by 1.1% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 12,603 shares of the medical research company’s stock after purchasing an additional 132 shares during the period. Chartwell Investment Partners LLC’s holdings in Laboratory Corp. of America were worth $1,928,000 as of its most recent SEC filing.

Several other institutional investors have also bought and sold shares of the business. Thrivent Financial for Lutherans increased its holdings in shares of Laboratory Corp. of America by 1.8% in the 4th quarter. Thrivent Financial for Lutherans now owns 4,471 shares of the medical research company’s stock worth $565,000 after purchasing an additional 78 shares in the last quarter. Bailard Inc. grew its holdings in shares of Laboratory Corp. of America by 5.2% in the fourth quarter. Bailard Inc. now owns 1,825 shares of the medical research company’s stock worth $231,000 after acquiring an additional 90 shares during the period. White Pine Investment CO grew its holdings in shares of Laboratory Corp. of America by 0.4% in the fourth quarter. White Pine Investment CO now owns 24,878 shares of the medical research company’s stock worth $3,144,000 after acquiring an additional 90 shares during the period. Lee Financial Group Hawaii Inc. grew its holdings in shares of Laboratory Corp. of America by 0.6% in the fourth quarter. Lee Financial Group Hawaii Inc. now owns 16,761 shares of the medical research company’s stock worth $2,118,000 after acquiring an additional 108 shares during the period. Finally, ETF Managers Group LLC grew its holdings in shares of Laboratory Corp. of America by 17.7% in the fourth quarter. ETF Managers Group LLC now owns 817 shares of the medical research company’s stock worth $103,000 after acquiring an additional 123 shares during the period. 91.50% of the stock is owned by institutional investors and hedge funds.

NYSE:LH opened at $159.07 on Tuesday. Laboratory Corp. of America Holdings has a 52-week low of $119.38 and a 52-week high of $190.35. The company has a debt-to-equity ratio of 0.87, a current ratio of 1.51 and a quick ratio of 1.38. The stock has a market cap of $15.58 billion, a price-to-earnings ratio of 14.43, a P/E/G ratio of 1.79 and a beta of 1.15.

Laboratory Corp. of America (NYSE:LH) last released its quarterly earnings results on Thursday, February 7th. The medical research company reported $2.52 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.48 by $0.04. Laboratory Corp. of America had a return on equity of 17.05% and a net margin of 8.43%. The business had revenue of $2.79 billion during the quarter, compared to analyst estimates of $2.78 billion. During the same quarter in the previous year, the company posted $2.45 earnings per share. Laboratory Corp. of America’s revenue for the quarter was up 1.6% on a year-over-year basis. Equities research analysts predict that Laboratory Corp. of America Holdings will post 11.22 EPS for the current year.

Several analysts recently commented on LH shares. UBS Group set a $178.00 price objective on Laboratory Corp. of America and gave the stock a “buy” rating in a report on Friday, February 8th. Morgan Stanley set a $175.00 price objective on Laboratory Corp. of America and gave the stock a “buy” rating in a report on Friday, February 22nd. Jefferies Financial Group raised Laboratory Corp. of America from a “hold” rating to a “buy” rating and lifted their price objective for the stock from $154.00 to $190.00 in a report on Tuesday, April 2nd. TheStreet lowered Laboratory Corp. of America from a “b-” rating to a “c+” rating in a report on Friday, January 11th. Finally, Zacks Investment Research raised Laboratory Corp. of America from a “sell” rating to a “hold” rating in a report on Wednesday, January 23rd. Two research analysts have rated the stock with a sell rating, eight have issued a hold rating and ten have assigned a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average price target of $175.50.

In other news, Director R Sanders Williams sold 1,038 shares of the business’s stock in a transaction dated Wednesday, February 13th. The stock was sold at an average price of $147.00, for a total value of $152,586.00. Following the transaction, the director now directly owns 8,924 shares in the company, valued at $1,311,828. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 0.74% of the stock is owned by insiders.

ILLEGAL ACTIVITY NOTICE: This news story was first posted by Watch List News and is the sole property of of Watch List News. If you are viewing this news story on another website, it was copied illegally and reposted in violation of US & international trademark and copyright law. The correct version of this news story can be accessed at https://www.watchlistnews.com/laboratory-corp-of-america-holdings-lh-shares-bought-by-chartwell-investment-partners-llc/2965364.html.

Laboratory Corp. of America Profile

Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. It operates in two segments, LabCorp Diagnostics (LCD) and Covance Drug Development. It offers various clinical laboratory tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C and vitamin D products, prostate-specific antigens, tests for sexually-transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests.

Featured Article: 52-Week High/Low

Want to see what other hedge funds are holding LH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Laboratory Corp. of America Holdings (NYSE:LH).

Institutional Ownership by Quarter for Laboratory Corp. of America (NYSE:LH)

Receive News & Ratings for Laboratory Corp. of America Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Corp. of America and related companies with MarketBeat.com's FREE daily email newsletter.